Design, Synthesis, and Biological Evaluation of Novel ML-167 Analogues as Therapeutic Candidates Against Sarcopenia-Induced Muscle Wasting
Abstract
Background: Sarcopenia is an aging-related syndrome characterized by loss of skeletal muscle mass, strength, and function, with no approved pharmacological treatment. This study aimed to design, synthesize, and evaluate novel ML-167 derivatives for sarcopenia-associated muscle wasting. Methods: ML-167 derivatives were synthesized and characterized by 1H NMR, 13C NMR, and mass spectrometry. Biological activity was evaluated in C2C12 myoblasts using MTT and Western blot assays. Selected compounds were evaluated in a dexamethasone-induced muscle wasting model. Muscle strength, mass, biochemical parameters, and histopathology were assessed. Structure-activity relationships were analysed using cell viability, molecular docking, and ligand efficiency data, alongside physicochemical properties. Results: Compounds 6b (116%), 3a (115%), 8d (114%), 4c (112%), 3m (112%), and 3c (111%) showed the highest C2C12 viability at 1 μM. Compounds 3a, 3c, and 6b increased MyH3 expression by approximately 1.6-1.7-fold, while MyoG remained near basal levels. In vivo, these compounds improved muscle strength, mass, and biochemical parameters without overt hepatic or renal abnormalities based on assessed serum and histopathological findings. Among the evaluated derivatives, compound 6b emerged as the most promising overall lead candidate, showing the greatest improvement in skeletal muscle mass and metabolic parameters, whereas compound 3c demonstrated the strongest histopathological protection and…
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.